MX2009014236A - Compuestos de bencensulfonamida adecuados para tratar transtornos que responden a la modulacion del receptor de dopamina d3. - Google Patents
Compuestos de bencensulfonamida adecuados para tratar transtornos que responden a la modulacion del receptor de dopamina d3.Info
- Publication number
- MX2009014236A MX2009014236A MX2009014236A MX2009014236A MX2009014236A MX 2009014236 A MX2009014236 A MX 2009014236A MX 2009014236 A MX2009014236 A MX 2009014236A MX 2009014236 A MX2009014236 A MX 2009014236A MX 2009014236 A MX2009014236 A MX 2009014236A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- fluorinated
- compounds
- formula
- dopamine
- Prior art date
Links
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title 1
- 150000008331 benzenesulfonamides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 12
- 150000003839 salts Chemical class 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 239000002253 acid Substances 0.000 abstract 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 229940088353 Dopamine D3 receptor antagonist Drugs 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229960003638 dopamine Drugs 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a los compuestos de la formula R1 seleccionada del grupo que consiste de hidrogeno, C1-C3 alquilo lineal y C1-C3 alquilo lineal fluorinado, R2 es hidrógeno o metilo, R3 es seleccionado del grupo que consiste de hidrógeno, halógeno, C1-C2-alquilo, C1-C2-alquilo fluorinado, C1-C2-alcoxi y C1-C2 alcoxi fluorinado, R es C1-C2-alquilo o C1-C2-alquilo fluorinado, n es 0, 1 ó 2, y las sales toleradas fisiológicamente de dichos compuestos y los N-óxidos de los mismos. La presente invención también se refiere a una composición farmacéutica que comprende al menos un compuesto de la fórmula I y/o al menos una sal de adición de ácido tolerada fisiológicamente del mismo, y además a un método para el tratamiento de padecimientos que respondan de manera benéfica a los antagonistas del receptor de dopamina D3 o agonistas de dopamina D3, dicho método comprende la administración de una cantidad efectiva de al menos un compuesto o una sal de adición de acido tolerada fisiológicamente de la formula I para un sujeto que la necesita.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07119788 | 2007-10-31 | ||
| PCT/EP2008/064732 WO2009056600A1 (en) | 2007-10-31 | 2008-10-30 | Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009014236A true MX2009014236A (es) | 2010-05-03 |
Family
ID=40280677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009014236A MX2009014236A (es) | 2007-10-31 | 2008-10-30 | Compuestos de bencensulfonamida adecuados para tratar transtornos que responden a la modulacion del receptor de dopamina d3. |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20100210664A1 (es) |
| EP (1) | EP2203426B9 (es) |
| JP (1) | JP5680416B2 (es) |
| KR (1) | KR20100080500A (es) |
| CN (1) | CN101687802B (es) |
| AT (1) | ATE522505T1 (es) |
| AU (1) | AU2008320875B2 (es) |
| BR (1) | BRPI0812978A2 (es) |
| CA (1) | CA2690976A1 (es) |
| CO (1) | CO6251289A2 (es) |
| CR (1) | CR11188A (es) |
| DO (1) | DOP2009000295A (es) |
| EC (1) | ECSP099832A (es) |
| ES (1) | ES2371308T3 (es) |
| GT (1) | GT200900332A (es) |
| IL (1) | IL202814A (es) |
| MX (1) | MX2009014236A (es) |
| MY (1) | MY153300A (es) |
| NZ (1) | NZ582095A (es) |
| RU (1) | RU2485103C2 (es) |
| TW (1) | TWI469782B (es) |
| UA (1) | UA99628C2 (es) |
| WO (1) | WO2009056600A1 (es) |
| ZA (1) | ZA200909171B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122023004130B1 (pt) * | 2013-06-27 | 2023-12-12 | Pfizer Inc | Compostos heteroaromáticos, composição farmacêutica e uso dos referidos compostos no tratamento de distúrbios mediados ou associados a dopamina d1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102439D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| US7320979B2 (en) * | 2003-04-14 | 2008-01-22 | Abbott Gmbh & Co. Kg. | N-[(piperazinyl)hetaryl]arylsulfonamide compounds |
| US20040204422A1 (en) * | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
-
2008
- 2008-10-30 AU AU2008320875A patent/AU2008320875B2/en not_active Ceased
- 2008-10-30 UA UAA201003729A patent/UA99628C2/ru unknown
- 2008-10-30 WO PCT/EP2008/064732 patent/WO2009056600A1/en active Application Filing
- 2008-10-30 CA CA2690976A patent/CA2690976A1/en not_active Abandoned
- 2008-10-30 ES ES08844327T patent/ES2371308T3/es active Active
- 2008-10-30 BR BRPI0812978-9A2A patent/BRPI0812978A2/pt not_active IP Right Cessation
- 2008-10-30 JP JP2010530492A patent/JP5680416B2/ja not_active Expired - Fee Related
- 2008-10-30 EP EP08844327A patent/EP2203426B9/en active Active
- 2008-10-30 US US12/666,627 patent/US20100210664A1/en not_active Abandoned
- 2008-10-30 RU RU2010121830/04A patent/RU2485103C2/ru not_active IP Right Cessation
- 2008-10-30 MX MX2009014236A patent/MX2009014236A/es active IP Right Grant
- 2008-10-30 NZ NZ582095A patent/NZ582095A/xx not_active IP Right Cessation
- 2008-10-30 AT AT08844327T patent/ATE522505T1/de not_active IP Right Cessation
- 2008-10-30 MY MYPI20095655A patent/MY153300A/en unknown
- 2008-10-30 TW TW97141857A patent/TWI469782B/zh not_active IP Right Cessation
- 2008-10-30 KR KR1020097027266A patent/KR20100080500A/ko active IP Right Grant
- 2008-10-30 CN CN200880023090.9A patent/CN101687802B/zh not_active Expired - Fee Related
-
2009
- 2009-12-17 IL IL202814A patent/IL202814A/en not_active IP Right Cessation
- 2009-12-22 ZA ZA2009/09171A patent/ZA200909171B/en unknown
- 2009-12-29 DO DO2009000295A patent/DOP2009000295A/es unknown
- 2009-12-29 EC EC2009009832A patent/ECSP099832A/es unknown
- 2009-12-29 CO CO09148550A patent/CO6251289A2/es not_active Application Discontinuation
- 2009-12-29 GT GT200900332A patent/GT200900332A/es unknown
-
2010
- 2010-01-04 CR CR11188A patent/CR11188A/es unknown
-
2011
- 2011-07-21 US US13/187,885 patent/US20110319421A1/en not_active Abandoned
-
2013
- 2013-12-04 US US14/096,565 patent/US20140200224A1/en not_active Abandoned
-
2014
- 2014-11-25 US US14/553,923 patent/US20150175570A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008115098A3 (fr) | 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation | |
| MX2009010731A (es) | Derivados de acido 1-(1-bencilpiperidin-4-il)benzimidazol-5-carbox ilico para el tratamiento de diabetes mellitus. | |
| MX2007012936A (es) | Derivados de dihidrobenzofurano y usos de los mismos. | |
| DE602005019043D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| MY141024A (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
| MX2009006474A (es) | Derivados de benzamida como agonistas del receptor ep4. | |
| UA99132C2 (ru) | Производные дикарбоновых кислот как агонисты рецепторов s1p1 | |
| WO2006057922A3 (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
| WO2007092364A3 (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
| GEP20135744B (en) | Quinuclidine carbonate derivatives and medicinal compositions containing the same | |
| TW200726764A (en) | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | |
| DE602006015509D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| PE20050460A1 (es) | COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO) | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| WO2007075749A3 (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
| MX2009005507A (es) | Derivados de espiro-piperidina. | |
| IL195409A0 (en) | 1,3-disubstituted 4-methyl-1h-pyrrole-2-carboxamides and their use for the manufacture of medicaments | |
| GEP20074256B (en) | Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing | |
| MX2009012518A (es) | Derivados de piperidina 4,4-disubstituidos. | |
| TW200633710A (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| MX2009005541A (es) | Indoles que actuan como antagonistas del receptor v1a. | |
| UA99634C2 (ru) | Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3 | |
| MY153733A (en) | Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same | |
| MX2009014236A (es) | Compuestos de bencensulfonamida adecuados para tratar transtornos que responden a la modulacion del receptor de dopamina d3. | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights |